{
    "clinical_study": {
        "@rank": "1665", 
        "arm_group": {
            "arm_group_label": "Sofosbuvir/Ledipasvir", 
            "arm_group_type": "Experimental", 
            "description": "Participants will receive SOF/LDV Fixed Dose Combination (FDC) for 24 weeks."
        }, 
        "brief_summary": {
            "textblock": "Aim of the study is to assess the efficacy and safety of 24 weeks of oral\n      Sofosbuvir/Ledipasvir fixed-dose combination (FDC) in subjects with HCV genotype 1 infection\n      and HIV co-infection, who have previously failed a NS3/4A protease inhibitor plus Pegylated\n      interferon /ribavirin regimen or stopped prematurely their treatment for intolerance."
        }, 
        "brief_title": "Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Viral Hepatitis C", 
            "HIV"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed HIV infection\n\n          -  Infection with HCV genotype 1 only, confirmed at screen visit, with a HCV-RNA \u2265 1000\n             InternationalUnit(IU)/mL at screen visit\n\n          -  Treatment-experienced subjects with:\n\n          -  previous virological failure to tritherapy with Peginterferon/Ribavirin and protease\n             inhibitor,\n\n          -  or premature discontinuation of previous tritherapy with\n\n          -  Peginterferon/Ribavirin and protease inhibitor due to intolerance to Peginterferon or\n             protease inhibitor\n\n          -  Anti-HCV treatment stopped for at least the last 3 months\n\n          -  Patients on a stable (for more than 1 month) antiretroviral treatment consisting of\n             an emtricitabine/tenofovir or lamivudine/tenofovir standard of care backbone plus\n             efavirenz or raltegravir or rilpivirine or enfuvirtide. Alternative combinations of\n             the above listed medications may be allowed.\n\n          -  Dendritic cells 4 > 100/mm3 and > 15% at screen visit\n\n          -  HIV-RNA  < 50cp/ml for more than 3 months at screen visit\n\n          -  Any liver fibrosis grade, with the assessment of the presence or not of cirrhosis at\n             screening, cirrhosis being defined as a METAVIR score of F4 on the liver puncture\n             biopsy and/or with hepatic impulse elastometry \u2265 15 kilopascal (kPa):\n\n          -  Previous liver biopsy exhibiting cirrhosis lesions (METAVIR F4),\n\n               -  and/or significant liver biopsy (cumulative length \u2265 15mm and \u2265 6 portal\n                  spaces), within the past 18 months\n\n               -  and/or significant and reliable liver stiffness assessment (Fibroscan\u00ae) within\n                  the past 6 months (at least 10 measures with IQR less than 25% of the mean value\n                  and a success rate of at least 80%).\n\n          -  Female patients with child-bearing potential, and their heterosexual partners must\n             use adequate contraception from the date of screening until 90 days after\n             administration of the last dose of study drug. Male participants must agree to\n             consistently and correctly use a condom, while their female partner must use adequate\n             contraception from the date of screening until 90 days after administration of the\n             last dose of study drug\n\n          -  Body weight \u226540 kg and \u2264125 kg\n\n          -  Informed and signed consent for the main study and the Pharmacokinetic (PK )\n             sub-study (for the participating patients)\n\n          -  Patients with Health insurance\n\n        Non inclusion Criteria:\n\n          -  Child-Pugh B or C cirrhosis or history of decompensated cirrhosis.\n\n          -  Co-infection with Hepatitis B virus (HBV) (AgHBs +) with HBV DNA > 1000 UI/ml\n\n          -  Pregnant or breast-feeding women\n\n          -  Transplant recipients\n\n          -  Opportunistic infections (stage C), active or occurred within 6 months prior to\n             baseline\n\n          -  Evolutive malignancy, including hepatocarcinoma which should be controlled prior to\n             baseline\n\n          -  Alcohol or drug consumption which may affect the study participation according to the\n             investigator. Patients included in a programme of substitution with methadone or\n             buprenorphine could be enrolled. The opinion of a consultant in addictology is\n             recommended for patients presenting with current drug use or drug use during the\n             previous year.\n\n          -  Patients with a history of non-adherence, who will be at risk of being unable to\n             respect the study follow-up timetable\n\n          -  Patients participating in another clinical trial within 30 days prior to inclusion\n\n          -  Hb < 10 g/dL (female) or < 11g/dL (male)\n\n          -  Platelets < 50 000/mm3\n\n          -  Neutrophil count < 750/mm3\n\n          -  Renal failure defined as creatinin clearance (MDRD) < 60ml/min\n\n          -  Other antiretroviral drugs than those allowed in the study\n\n          -  Contra-indications to Sofosbuvir, Ledipasvir\n\n          -  Contra-indicated treatment likely to interfere with the study drugs as listed in the\n             protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02125500", 
            "org_study_id": "ANRS HC31 SOFTRIH"
        }, 
        "intervention": {
            "arm_group_label": "Sofosbuvir/Ledipasvir", 
            "description": "SOF 400 mg/LDV 90 mg FDC tablet administered orally once daily", 
            "intervention_name": "Sofosbuvir/Ledipasvir fixed dose", 
            "intervention_type": "Drug", 
            "other_name": [
                "Sofosbuvir is also known as GS-7977 or PSI-7977.", 
                "Ledipasvir is also known as GS-5885."
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Protease Inhibitors"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HCV/HIV coinfection", 
            "HCV genotype 1"
        ], 
        "lastchanged_date": "April 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rennes", 
                    "country": "France"
                }, 
                "name": "Centre de M\u00e9thodologie et de Gestion de Rennes"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir (GS-5885) Fixed-dose Combination in NS3/4A Protease Inhibitor-experienced Subjects With HCV Genotype 1 Infection and HIV Co-infection", 
        "overall_contact": {
            "email": "rosenthal.e@chu-nice.fr", 
            "last_name": "Eric Rosenthal", 
            "phone": "+33", 
            "phone_ext": "4 92 035851"
        }, 
        "overall_contact_backup": {
            "email": "Claire.FOUGEROU@chu-rennes.fr", 
            "last_name": "Claire Fougerou-Leurent", 
            "phone": "+33", 
            "phone_ext": "299283753"
        }, 
        "overall_official": [
            {
                "affiliation": "H\u00f4pital de Nice", 
                "last_name": "Eric Rosenthal", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centre de M\u00e9thodologie et de Gestion, CHU de Rennes", 
                "last_name": "Eric Bellissant", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Sustained virologic response 12 weeks after discontinuation of therapy (SVR12), i.e. at week 36.", 
            "safety_issue": "No", 
            "time_frame": "12 weeks post-treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02125500"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Adverse clinical and biological events that occur during the treatment and up to 24 weeks after the end of the treatment", 
                "safety_issue": "Yes", 
                "time_frame": "up to 24 weeks after the end of the treatment"
            }, 
            {
                "measure": "Number and causes of poor adherence and treatment interruptions", 
                "safety_issue": "No", 
                "time_frame": "at 1,2,3,4,8,12,16, 20, 24 weeks during treatment, 4, 8,14,18,24 weeks after treatment discontinuationeeks after discontinuation of drugs"
            }, 
            {
                "measure": "SVR rate 24 weeks (i.e. W48) after the end of treatment and according to the HCV sub-type", 
                "safety_issue": "No", 
                "time_frame": "Week 48"
            }, 
            {
                "measure": "Number of patients with HCV resistance mutations to Sofosbuvir and/or Ledipasvir", 
                "safety_issue": "No", 
                "time_frame": "from Day(D)0 to Week (W)24"
            }, 
            {
                "measure": "HCV viral load", 
                "safety_issue": "No", 
                "time_frame": "at D0, W1, W2, W4, W8, W12, W16, W20, W24, and 4, 8, 12, 18 and 24 weeks after the end of the treatment"
            }, 
            {
                "measure": "Plasma HIV RNA levels", 
                "safety_issue": "No", 
                "time_frame": "at D0, W4, W8, W12, W16, W20, W24, W36 and W48"
            }, 
            {
                "description": "Describe pharmacokinetic parameters of HIV drugs at D0 and W4 Describe pharmacokinetic parameters  of Sofosbuvir and Ledipasvir at W4", 
                "measure": "Assess drug-drug interactions between HCV et HIV drugs", 
                "safety_issue": "No", 
                "time_frame": "D0 and W4"
            }, 
            {
                "measure": "Patient's reported outcomes evaluation", 
                "safety_issue": "No", 
                "time_frame": "D0,W8, W24 and W48"
            }
        ], 
        "source": "French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}